view original post

BioNTech SE (NASDAQ:BNTX) traded at $211.84 at close of the session on Friday, 01/07/22, made a downward move of -1.35% on its previous day’s price.

Looking at the stock we see that its previous close was $214.74 and the beta (5Y monthly) reads -1.25 with the day’s price range being $209.27 – $217.73. The company has a trailing 12-month PE ratio of 6.34. In terms of its 52-week price range, BNTX has a high of $464.00 and a low of $90.29. The company’s stock has lost about -27.44% over that past 30 days.


3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


BioNTech SE has a market cap of $52.08 billion and is expected to release its quarterly earnings report on Nov 09, 2021. Estimates by analysts give the company expected earnings per share (EPS) of $8.52, with the EPS growth for the year raised at $41.2 for 2021 and $39.67 for next year. These figures represent 58,757.10% and -3.70% growth in EPS for the two years respectively.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $4.57 billion, with a low of $3.89 billion and a high of $6.07 billion. The median projection represents growth squeezing down to 981.70% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $19.64 billion, or 3,229.50% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the BNTX stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 50% Sell.

Looking further, we note the current price level is -17.73% off its SMA20 and -22.96% from its 50-day simple moving average. The RSI (14) is pointing at 33.33 while the volatility over the past week is 7.99% and jumps to 6.80% over the past one month.

Coming back to BioNTech SE (NASDAQ:BNTX), we note that the average 3-month trading volume was 3.25 million, while that of the preceding 10-day period stands at 2.45 million. Current shares outstanding are 244.37 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

The insiders hold 66.88% of the company’s shares while institutions hold 17.20%. The data shows that short shares as of Dec 14, 2021, stood at 2.17 million at a short ratio of 0.52. This represents a 0.89% short interest in shares outstanding on Dec 14, 2021. Shares short fall in December from the previous month at 3.19 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -17.83% down in year-to-date price movement.